相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Christopher A. Muir et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment
Christopher A. Muir et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors
Chiaki Kurimoto et al.
CANCER SCIENCE (2020)
PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients
Anupam Kotwal et al.
THYROID (2020)
Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients
Edwin A. Basak et al.
THYROID (2020)
Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
Christopher A. Muir et al.
THYROID (2020)
Immune-related adverse events of checkpoint inhibitors
Manuel Ramos-Casals et al.
NATURE REVIEWS DISEASE PRIMERS (2020)
Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction
Anna Olsson-Brown et al.
ENDOCRINE CONNECTIONS (2020)
Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints
Lee-Shing Chang et al.
ENDOCRINE REVIEWS (2019)
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab
Ichiro Yamauchi et al.
PLOS ONE (2019)
Analysis of the PD-1/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity
Daniel Alvarez-Sierra et al.
JOURNAL OF AUTOIMMUNITY (2019)
Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer
Yukihiro Toi et al.
JAMA ONCOLOGY (2019)
Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
Hye In Kim et al.
ONCOIMMUNOLOGY (2018)
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
Sara Valpione et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Michael A. Postow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab
Shiro Kimbara et al.
CANCER SCIENCE (2018)
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Priyanka C. Iyer et al.
THYROID (2018)
Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity
Ryota Tanaka et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Ichiro Yamauchi et al.
THYROID (2017)
RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB
Grenye O'Malley et al.
ENDOCRINE PRACTICE (2017)
Current concepts: Thyroiditis
EN Pearce et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
分享论文
